OPEN END TURBO SHORT - BIOMERIEUX Share Price

Certificat

DE000MB9E1F1

Real-time Bid/Ask 04:59:13 26/06/2024 pm IST
2.78 EUR / 2.79 EUR +1.64% Intraday chart for OPEN END TURBO SHORT - BIOMERIEUX
Current month+22.32%
1 month+13.69%
Date Price Change
26/24/26 2.75 +0.36%
25/24/25 2.74 -4.20%
24/24/24 2.86 -4.03%
21/24/21 2.98 +4.56%
20/24/20 2.85 -1.72%

Delayed Quote Börse Stuttgart

Last update June 26, 2024 at 04:09 pm IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying BIOMÉRIEUX
Issuer Morgan Stanley
WKN MB9E1F
ISINDE000MB9E1F1
Date issued 02/08/2023
Strike 118.9
Maturity Unlimited
Parity 10 : 1
Emission price 2.31
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 3.51
Lowest since issue 1.36
Spread 0.01
Spread %0.36%

Company Profile

bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Sector
-
More about the company

Ratings for bioMérieux

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: bioMérieux

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
91.2 EUR
Average target price
113.5 EUR
Spread / Average Target
+24.43%
Consensus